Endovascular Treatment of Aorto-iliac Occlusions

January 29, 2019 updated by: Vladimir Cvetic, Clinical Centre of Serbia

Endovascular Treatment of Different Types of Aorto-iliac Occlusions

This study compares early and long-term results of the endovascular treatment among patients with different types of aorto-iliac occlusions.

Study Overview

Detailed Description

Endovascular treatment has been increasingly applied as a therapeutic option for aorto-iliac occlusive disease during the last decade, becoming the first-line treatment for many of the Trans-Atlantic Inter-Society Consensus document II (TASC II) categories. TASC II document in 2007 stated endovascular treatment as the method of choice up to type B occlusions and surgery for low-risk patients with type C and D occlusions, emphasizing that the patient's comorbidities as well as the operator's long-term success rates should be included in the decision-making process.

Revision of TASC II document in 2015 is suggesting that the preferred revascularization method should be based on each vascular center's competence and experience with the anatomic complexity, considering patient comorbidity and overall prognosis, supporting the endovascular-first approach in all 4 different kinds of lesions in highly experienced centers.

These changes over time are based on expert opinions derived from smaller studies from high volume centers, and that they reflect both the widespread gain of endovascular experience and technical developments over the last 2 decades, leading to a rising number of centers providing an endovascular-first approach even in complex TASC C and D occlusions.

Rationale for offering endovascular-first option to patient with complex lesion would be low risk of complication and long-term patency.

Our intention is to compare early and long-term results of the endovascular treatment among patients with different types of aorto-iliac occlusions in two Serbian vascular centres.

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Belgrade, Serbia, 11000
        • Clinical Center of Serbia
      • Belgrade, Serbia, 11000
        • Institute for Cardiovascular Diseases Dedinje

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients treated with endovascular stent due to aorto-iliac occlusions

Description

Inclusion Criteria:

  • Patient has aorto-iliac occlusions type B, C & D according to TASC-II classification
  • Patient suffers from severe claudication (Rutherford 3) or critical limb ischemia (Rutherford 4 and 5)
  • Patients fulfilling criteria for endovascular treatment of aorto-iliac occlusion according to criteria of the participating centres.

Exclusion Criteria:

  • Patients with associated abdominal or iliac aneurysm, restenotic lesions, acute thrombi or dissections,
  • Patients who experienced an initial technical failure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Endovascular occlusions group
Group of patients with aorto-iliac occlusive disease (TASC B, C, D) in whom stenting of the Common and/or External Iliac Arteries were performed

Stenting of the Common and/or External Iliac Arteries was performed in the angiographic suite. Under local anesthesia, arterial access was obtained through standard percutaneous puncture of the common femoral artery, brachial approach, or simultaneous brachial and femoral approach.

Iliac lesion crossing was achieved through intraluminal or subintimal manner depending on the behavior of the lesion intraoperatively.

Predilatation of the occlusion before stent deployment was performed at the discretion of the operator.

Balloon-expandable stents were used for proximal, ostial lesions, whereas self-expanding stents were deployed in all other lesions.

Both stents were used in long lesions involving heavily calcified common iliac arteries.

Other Names:
  • Percutaneous Transluminal Angioplasty
  • stent implantation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary artery/stent patency rate
Time Frame: 60 Months
Patients were assumed primary patent if the target vessel had continuous flow without revascularization, bypass, or amputation.
60 Months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary assisted artery/stent patency rate
Time Frame: 60 months
Primary assisted patency is defined as continuous flow assisted with a revascularization when the target vessel has restenosed (>70%) at any time post-procedure.
60 months
Secondary patency artery/stent rate
Time Frame: 60 months
Secondary patency is defined as reestablishment of flow to distal arteries after 100% occlusion has occurred at the target vessel at any time post-procedure
60 months
Clinical success
Time Frame: 60 months
During the follow-up period, the improvement of Rutherford classification 1 grade or more than 1 grade.
60 months
Number of participants with periprocedural complications: hematoma, bleeding, pseudoaneurysm, renal failure, myocardial infarction, stroke, mortality, thrombosis of the treated segment
Time Frame: 1 month
Identification of serious adverse events requiring correction of therapy or surgery. Will be used physiological parameter and questionnaire.
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Dragan Z Sagic, Prof, Institute for Cardiovascular Diseases Dedinje

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2013

Primary Completion (ACTUAL)

November 1, 2017

Study Completion (ACTUAL)

September 1, 2018

Study Registration Dates

First Submitted

January 25, 2019

First Submitted That Met QC Criteria

January 29, 2019

First Posted (ACTUAL)

January 31, 2019

Study Record Updates

Last Update Posted (ACTUAL)

January 31, 2019

Last Update Submitted That Met QC Criteria

January 29, 2019

Last Verified

January 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • CCSerbia Vasc

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Iliac Artery Occlusion

Clinical Trials on Stenting of the Common and/or External Iliac Arteries

3
Subscribe